Line 2,216: |
Line 2,216: |
| | | | | |
| |}<br /> | | |}<br /> |
| + | |
| + | ==WHO Classification of Tumours of the Central Nervous System Content== |
| + | {| class="wikitable" |
| + | |- |
| + | !'''Disease'''!!'''Page Type'''!!'''Author''' |
| + | !'''Date Assigned to Author''' |
| + | !'''Target Completion Date''' |
| + | !'''Author Content (Pending or Complete)''' |
| + | !'''Date Completed by Author'''!!'''Associate Editor''' |
| + | !'''Date of Last Editor Review''' |
| + | !'''Notes''' |
| + | |- |
| + | |Medulloblastoma, WNT-activated||Disease||Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City |
| + | |9/20/21 |
| + | | |
| + | |COMPLETE |
| + | | |
| + | |Holli Drendel (interim)/Laveniya Satgunaseelan (LS) |
| + | |9/22/2022 |
| + | |2021 template added |
| + | |- |
| + | |Paediatric-Type Diffuse High-Grade Gliomas |
| + | |Overview |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |2021 template added |
| + | |- |
| + | |Diffuse Midline Glioma, H3 K27-Altered |
| + | |Disease |
| + | |Laveniya Satgunaseelan (Linda Cooley - previous version) |
| + | | |
| + | | |
| + | |PENDING |
| + | | |
| + | |Laveniya Satgunaseelan (LS) |
| + | | |
| + | |2021 template added |
| + | |- |
| + | |Diffuse Hemispheric Glioma, H3 G34-Mutant |
| + | |Disease |
| + | |Xiaolin (Lynn) Hu |
| + | |2/21/2022 |
| + | | |
| + | |PENDING |
| + | | |
| + | |LS |
| + | | |
| + | |2021 template added |
| + | |- |
| + | |Diffuse Paediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype |
| + | |Disease |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |2021 template added |
| + | |- |
| + | |Infant-Type Hemispheric Glioma |
| + | |Disease |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |2021 template added |
| + | |- |
| + | |Astrocytoma, IDH-Mutant |
| + | |Disease |
| + | |Riley Lochner (trainee), Shashi Shetty (mentor) |
| + | |3/3/2022 |
| + | | |
| + | |PENDING |
| + | | |
| + | |LS |
| + | | |
| + | |2021 template added |
| + | |- |
| + | |Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted |
| + | |Disease |
| + | |Riley Lochner (trainee), Shashi Shetty (mentor) |
| + | |3/3/2022 |
| + | | |
| + | |PENDING |
| + | | |
| + | |LS |
| + | | |
| + | |2021 template added |
| + | |- |
| + | |Ganglioglioma |
| + | |Disease |
| + | |Leila Moayed-Aloei |
| + | |6/30/2022 |
| + | | |
| + | |PENDING |
| + | | |
| + | |LS |
| + | | |
| + | |2021 template added |
| + | |- |
| + | |Pilocytic Astrocytoma |
| + | |Disease |
| + | |Jeremy Pulvers |
| + | |9/13/2022 |
| + | | |
| + | |PENDING |
| + | | |
| + | |LS |
| + | | |
| + | |2021 template added |
| + | |- |
| + | |}<br /> |
| + | |
| + | ==WHO Classification of Soft Tissue and Bone Tumours Content== |
| + | {| class="wikitable" |
| + | |- |
| + | !'''Disease'''!!'''Page Type'''!!'''Author''' |
| + | !'''Date Assigned to Author''' |
| + | !'''Target Completion Date''' |
| + | !'''Author Content (Pending or Complete)''' |
| + | !'''Date Completed by Author'''!!'''Associate Editor''' |
| + | !'''Date of Last Editor Review''' |
| + | !'''Notes''' |
| + | |- |
| + | |NTRK-Rearranged Spindle Cell Neoplasm||Disease||James Solomon, MD, PhD |
| + | |2/20/2022 |
| + | | |
| + | |PENDING |
| + | | |
| + | |Alanna Church |
| + | | |
| + | | |
| + | |- |
| + | |}<br /> |
| + | |
| + | ==WHO Classification of Tumours of Breast Tumours Content== |
| + | {| class="wikitable" |
| + | |- |
| + | !'''Disease'''!!'''Page Type'''!!'''Author''' |
| + | !'''Date Assigned to Author''' |
| + | !'''Target Completion Date''' |
| + | !'''Author Content (Pending or Complete)''' |
| + | !'''Date Completed by Author'''!!'''Associate Editor''' |
| + | !'''Date of Last Editor Review''' |
| + | !'''Notes''' |
| + | |- |
| + | |Adenoid Cystic Carcinoma |
| + | |Disease||Katherine Geiersbach |
| + | |10/12/02022 |
| + | | |
| + | |PENDING |
| + | | |
| + | |Hui Chen |
| + | | |
| + | |2021 template added |
| + | |- |
| + | |Secretory Carcinoma |
| + | |Disease |
| + | |Hui Chen |
| + | |10/12/2022 |
| + | | |
| + | |PENDING |
| + | | |
| + | |Katherine Geiersbach |
| + | | |
| + | |2021 template added |
| + | |- |
| + | |}<br /> |
| + | |
| + | ==Gene-Specific Pages (IN PROCESS OF AUTOMATING - HOLD ON VOLUNTEERING)== |
| + | {| class="wikitable sortable" |
| + | !'''Gene''' |
| + | !'''Author''' |
| + | !'''Date Assigned to Author''' |
| + | !'''Target Completion Date''' |
| + | !'''Author Content (Pending or Complete)''' |
| + | !'''Date Completed by Author''' |
| + | !'''Associate Editor''' |
| + | !'''Date of Last Editor Review''' |
| + | !'''Notes''' |
| + | |- |
| + | |BCR |
| + | |Brian Davis |
| + | | |
| + | | |
| + | |Complete |
| + | |8/10/18 |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |ABL1 |
| + | |Brian Davis |
| + | | |
| + | | |
| + | |Complete |
| + | |4/16/19 |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |RUNX1 |
| + | |Brian Davis |
| + | | |
| + | | |
| + | |Complete |
| + | |6/9/19 |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |RUNX1T1 |
| + | |Brian Davis |
| + | | |
| + | | |
| + | |Complete |
| + | |5/23/19 |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |MYH11 |
| + | |Brian Davis |
| + | | |
| + | | |
| + | |Complete |
| + | |8/6/18 |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |FLT3 |
| + | |Kay Weng Choy |
| + | | |
| + | | |
| + | |Complete |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |NPM1 |
| + | |Kay Weng Choy |
| + | | |
| + | | |
| + | |Complete |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |TP53 |
| + | |Kay Weng Choy |
| + | | |
| + | | |
| + | |Complete |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |DNMT3A |
| + | |Kay Weng Choy |
| + | | |
| + | | |
| + | |Complete |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |CEBPA |
| + | |Gordana |
| + | | |
| + | | |
| + | |Complete |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |IDH1 |
| + | |Paul De Fazio |
| + | | |
| + | | |
| + | |Complete |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |IDH2 |
| + | |Paul De Fazio |
| + | | |
| + | | |
| + | |Complete |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |PML |
| + | |Brian Davis |
| + | | |
| + | | |
| + | |Complete |
| + | |12/5/18 |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |RARA |
| + | |Brian Davis |
| + | | |
| + | | |
| + | |Complete |
| + | |8/3/18 |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |ETV6 |
| + | |Brian Davis |
| + | | |
| + | | |
| + | |Complete |
| + | |6/9/19 |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |KIT |
| + | |Brian Davis |
| + | | |
| + | | |
| + | |Complete |
| + | |10/1/18 |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |CBFB |
| + | |Brian Davis |
| + | | |
| + | | |
| + | |Complete |
| + | |8/2/18 |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |GATA2 |
| + | |Kay Weng Choy |
| + | | |
| + | | |
| + | |Complete |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |PTEN |
| + | |Beth Pitel |
| + | | |
| + | | |
| + | |Pending |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |MLTT3 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |MECOM |
| + | |Brian Davis |
| + | | |
| + | | |
| + | |Pending |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |FGFR1(FLT2) |
| + | |Brian Davis |
| + | | |
| + | | |
| + | |Pending |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |KMT2A |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |DEK |
| + | |Wahab A. Khan |
| + | | |
| + | | |
| + | |Pending |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |NUP214 |
| + | |Wahab A. Khan |
| + | | |
| + | | |
| + | |Pending |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |RBM15 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |MKL1 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |DDX41 |
| + | |Ying Zou |
| + | |8/7/20 |
| + | | |
| + | |Pending |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |ANKRD26 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |CUX1 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |TET2 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |EZH2 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |FOXP1 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |MYC |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |JAK2 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |WT1 |
| + | |DONE |
| + | | |
| + | | |
| + | |DONE |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |CBL |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |NF1 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |SUZ12 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |ERG |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |EST2 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |RPS14 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |RB1 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |MPL |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |CHGA |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |CDH1 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |SRSF2 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |DNMT1 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |PRDX2 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |ASXL1 |
| + | |DONE |
| + | | |
| + | | |
| + | |DONE |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |MN1 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |SF3A1 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |EP300 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |JARID2 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |BRCA1 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |BRCA2 |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |} |
| | | |
| ==WHO Central Nervous System Tumours (5th ed.) Content== | | ==WHO Central Nervous System Tumours (5th ed.) Content== |
Line 3,317: |
Line 4,087: |
| |- | | |- |
| } | | } |
| + | |
| + | |